In-lesion restenosis is similar between the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus) when used for the treatment of routine coronary artery stenoses, but the sirolimus-eluting stent may offer an advantage in patients with diabetes, according to a study reported at the ACC Annual Scientific Session 2005.
In the international head-to-head trial, called REALITY, 1,386 patients were randomized to receive either the sirolimus- or paclitaxel-eluting stent. To be eligible, patients had to have 1 or 2 de novo lesions in a native coronary artery. Twenty-eight percent of the study population had diabetes.
The primary end point, the in-lesion binary restenosis rate as determined by quantitative coronary angiography at 8 months post-procedure, was achieved in 9.6% of patients who received the sirolimus stent and 11.1% who received the paclitaxel stent, a nonsignificant difference (P=.31).
The other angiographic parameters, however, did favor more robust inhibition of neointimal hyperplasia with the sirolimus stent, including less late loss (0.09 vs 0.31 mm, P<.001), a lower percent diameter stenosis (23.1% vs 26.7%, P<.001), and a greater mean lumen diameter (2.00 vs 1.85 mm, P<.001).
In addition, a greater number of acute and subacute stent thromboses occurred with the paclitaxel-eluting stent than with the sirolimus-eluting stent (1.8% vs 0.4%, P=.0196), which is the first indication of a "significant safety difference between drug-eluting stents," Dr Morice said.
A single-center study demonstrated that the sirolimus-eluting stent was more effective than the paclitaxel-eluting stent in preventing restenosis in the high-risk subset of patients with diabetes, said Adnan Kastrati, MD, from the Deutches Herzzentrum, Munich, Germany.
The study included 250 patients with diabetes who had angina or a positive stress test in the presence of 50% stenosis in native coronary vessels. Those patients were randomized to receive 1 of the stents and followed to 6 months with an angiographic assessment of late lumen loss, and to 9 months to compare the rate of clinical events.
In-segment late lumen loss was significantly less in the patients randomized to the sirolimus- vs the paclitaxel-eluting stent (0.43 vs 0.67 mm, P<.0001), as was in-stent late lumen loss (0.19 vs 0.46 mm, P<.0001). Angiographic restenosis occurred in 6.9% vs 16.5% (P=.03) of patients randomized to the sirolimus and paclitaxel stents, respectively.
At 9 months, the rates of mortality and myocardial infarction were not significantly different between the 2 groups.
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More